PortfoliosLab logoPortfoliosLab logo
CRSP vs. VRTX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CRSP vs. VRTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRSP achieves a -5.03% return, which is significantly lower than VRTX's -1.86% return.


CRSP

1D
-0.86%
1M
2.87%
YTD
-5.03%
6M
-12.14%
1Y
20.41%
3Y*
-6.43%
5Y*
-17.08%
10Y*

VRTX

1D
-0.03%
1M
1.83%
YTD
-1.86%
6M
-1.57%
1Y
-2.31%
3Y*
9.16%
5Y*
18.18%
10Y*
17.15%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CRSP vs. VRTX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRSP
CRISPR Therapeutics AG
-5.03%33.23%-37.12%54.00%-46.36%-50.51%151.39%113.18%21.68%15.89%
VRTX
Vertex Pharmaceuticals Incorporated
-1.86%12.58%-1.03%40.90%31.50%-7.08%7.94%32.13%10.58%103.42%

Correlation

The correlation between CRSP and VRTX is 0.41, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.41

Correlation (3Y)
Calculated over the trailing 3-year period

0.31

Correlation (5Y)
Calculated over the trailing 5-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Oct 19, 2016

0.34

Fundamentals

Market Cap

CRSP:

$4.78B

VRTX:

$114.03B

EPS

CRSP:

-$6.24

VRTX:

$16.87

PS Ratio

CRSP:

1.11K

VRTX:

9.34

PB Ratio

CRSP:

2.64

VRTX:

4.31

Total Revenue (TTM)

CRSP:

$4.10M

VRTX:

$12.26B

Gross Profit (TTM)

CRSP:

-$171.17M

VRTX:

$10.57B

EBITDA (TTM)

CRSP:

-$509.21M

VRTX:

$5.19B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRSP vs. VRTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP
CRSP Risk / Return Rank: 5454
Overall Rank
CRSP Sharpe Ratio Rank: 5555
Sharpe Ratio Rank
CRSP Sortino Ratio Rank: 5555
Sortino Ratio Rank
CRSP Omega Ratio Rank: 5252
Omega Ratio Rank
CRSP Calmar Ratio Rank: 5454
Calmar Ratio Rank
CRSP Martin Ratio Rank: 5353
Martin Ratio Rank

VRTX
VRTX Risk / Return Rank: 3737
Overall Rank
VRTX Sharpe Ratio Rank: 3939
Sharpe Ratio Rank
VRTX Sortino Ratio Rank: 3434
Sortino Ratio Rank
VRTX Omega Ratio Rank: 3535
Omega Ratio Rank
VRTX Calmar Ratio Rank: 3838
Calmar Ratio Rank
VRTX Martin Ratio Rank: 3737
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. VRTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CRSPVRTXDifference
Sharpe ratioReturn per unit of total volatility

+0.43

Sortino ratioReturn per unit of downside risk

+0.84

Omega ratioGain probability vs. loss probability

1.11

1.02

+0.09

Calmar ratioReturn relative to maximum drawdown

0.49

-0.14

+0.63

Martin ratioReturn relative to average drawdown

0.81

-0.29

+1.10

CRSP vs. VRTX - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.33, which is higher than the VRTX Sharpe Ratio of -0.10. The chart below compares the historical Sharpe Ratios of CRSP and VRTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CRSP vs. VRTX - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for CRSP and VRTX.


Loading charts...

Drawdown Indicators


CRSPVRTXDifference

Max Drawdown

Largest peak-to-trough decline

-85.11%

-91.77%

+6.66%

Max Drawdown (1Y)

Largest decline over 1 year

-42.25%

-23.56%

-18.69%

Max Drawdown (3Y)

Largest decline over 3 years

-64.91%

-29.07%

-35.84%

Max Drawdown (5Y)

Largest decline over 5 years

-80.68%

-29.07%

-51.61%

Max Drawdown (10Y)

Largest decline over 10 years

-41.60%

Current Drawdown

Current decline from peak

-76.29%

-13.90%

-62.39%

Average Drawdown

Average peak-to-trough decline

-49.24%

-37.73%

-11.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

25.51%

11.30%

+14.21%

Volatility

CRSP vs. VRTX - Volatility Comparison

CRISPR Therapeutics AG (CRSP) has a higher volatility of 18.22% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 7.47%. This indicates that CRSP's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRSPVRTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.22%

7.47%

+10.75%

Volatility (6M)

Calculated over the trailing 6-month period

43.62%

20.71%

+22.91%

Volatility (1Y)

Calculated over the trailing 1-year period

62.44%

34.13%

+28.31%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

60.65%

28.53%

+32.12%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

64.35%

32.82%

+31.53%

Dividends

CRSP vs. VRTX - Dividend Comparison

Neither CRSP nor VRTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CRSP vs. VRTX - Financials Comparison

This section allows you to compare key financial metrics between CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B3.00B3.50B20222023202420252026
1.46M
2.99B
(CRSP) Total Revenue
(VRTX) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CRSP and VRTX have a correlation of 0.41, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CRSP has higher volatility (18.22%) compared to VRTX (7.47%). In terms of maximum drawdown, CRSP dropped -85.11% vs VRTX's -91.77%.

CRSP currently has the higher Sharpe Ratio (0.33 vs -0.10), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRSP and VRTX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer